The market is segmented based on technology, application, end-users, and geography. By technology, this market is categorized into monoclonal antibodies, cytokines & immunomodulators, and other technologies. By application, it is classified into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and other applications. By end-users, it is divided into hospitals, cancer research centers, and clinics. Geographically, it is studied across North America, Europe, Asia Pacific, and LAMEA.
KEY MARKET BENEFITS:
Comprehensive analysis of factors that drive and restrict the growth of the global cancer immunotherapy market is provided.
The projections in the market are made by studying the current market trends and future market potential for the period (2014-2022) in terms of value.
Extensive analysis by technology and application helps understand the various trends and prevailing opportunities in the respective market
Key market players within the global cancer immunotherapy market are profiled in the market and their strategies are analyzed thoroughly, which helps understand the competitive outlook of the global cancer immunotherapy market.
Comprehensive analysis of all regions are provided that determines the prevailing opportunities in these geographies.
KEY MARKET SEGMENT:
Cytokines & Immunomodulators
Others (Immune Checkpoint Inhibitors, Cell Therapy, and Oncolytic Virus Immunotherapy)
Head & Neck Cancer
Others (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma)
Cancer Research Centres
List of players profiled in the report
F. Hoffmann-La Roche AG.
Merck & Co., Inc.
Eli Lilly and Company
Bristol-Myers Squibb Company
List of other players (These companies are not profiled in the report and same can be done on demand)
Takeda Pharmaceutical Company Ltd.
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENT
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.5. ANALYST TOOLS AND MODELS
CHAPTER 2 EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry
3.4. MARKET SHARE ANALYSIS OF CANCER IMMUNOTHERAPY MARKET, 2015
3.5. MARKET DYNAMICS
CHAPTER 4 CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY
4.1.1. Market Size and Forecast
4.2. MONOCLONAL ANTIBODIES
4.2.1. Key Market Trends
4.2.2. Key Growth Factors and Opportunities
4.2.3. Market Size and Forecast
4.4. CYTOKINES & IMMUNOMODULATORS
4.4.1. Key Market Trends
4.4.2. Key Growth Factors And Opportunities
4.4.3. Market Size And Forecast
4.5. OTHER TECHNOLOGY
4.5.1. Key Market Trends
4.5.2. Key Growth Factors And Opportunities
4.5.3. Market Size And Forecast
CHAPTER 5 CANCER IMMUNOTHERAPY MARKET, BY APPLICATION
5.1.1. Market size and forecast
5.2. LUNG CANCER
5.2.1. Market size and forecast
5.3. BREAST CANCER
5.3.1. Market size and forecast
5.4. COLORECTAL CANCER
5.4.1. Market size and forecast
5.5.1. Market size and forecast
5.6. PROSTATE CANCER
5.6.1. Market size and forecast
5.7. HEAD & NECK CANCER
5.7.1. Market size and forecast
5.8. OTHER CANCER
5.8.1. Market size and forecast
CHAPTER 6 CANCER IMMUNOTHERAPY MARKET, BY END USER
6.1.1. Market size and forecast
6.2.1. Market size and forecast
6.3. CANCER RESEARCH CENTERS
6.3.1. Market size and forecast
6.4.1. Market size and forecast
CHAPTER 7 MULTIPLEX ASSAYS MARKET, BY GEOGRAPHY
7.1.1. Market size and forecast
7.2. NORTH AMERICA
7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S. market size and forecast
7.2.5. Canada market size and forecast
7.2.6. Mexico market size and forecast
7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany market size and forecast
7.3.5. France market size and forecast
7.3.6. UK market size and forecast
7.3.7. Italy market size and forecast
7.3.8. Spain market size and forecast
7.3.9. Rest of Europe market size and forecast
7.4.1. Key market trends
7.4.2. Key growth factors and opportunities.
7.4.3. Market size and forecast
7.4.4. Japan market size and forecast
7.4.5. China market size and forecast
7.4.6. India market size and forecast
7.4.7. Rest of Asia-Pacific market size and forecast
7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Latin America market size and forecast
7.5.5. Middle East market size and forecast
7.5.6. Africa market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1. AMGEN INC.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. ADVAXIS INC.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. MERCK & CO., INC.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments
8.4. ELI LILLY AND COMPANY
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. BRISTOL-MYERS SQUIBB COMPANY
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments
8.6. PFIZER INC.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. NOVARTIS AG
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. BAYER AG
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. IMMUNOMEDICS INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. ASTRAZENECA PLC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
Cancer immunotherapy, also known as biologic therapy, helps in cancer treatment by boosting the immunity of the body to fight against cancer. In this type of therapy antibodies and live viruses are introduced in the body that slows the growth of cancer cells. In addition, it also helps the immune system destroy the cancer cells. The major factors that drive the growth of this market include increase in incidence of cancers, growth in geriatric population, and rise in cancer R&D. However, shortage of skilled labor and lack of awareness about cancer immunotherapy is projected to restrain the market growth during the forecast period.
The cancer immunotherapy market in this report is studied on the basis of technology, application, end-user, and region. Based on technology, the market is divided into monoclol antibodies, cytokines & immunomodulators, and other technologies. Monoclol antibodies held the largest share in 2015 owing to high usage of monoclol antibodies for cancer immunotherapy as they exhibit different immunomodulatory properties and hence they can directly activate or inhibit the molecules of immune system. In addition, monoclol antibodies also induce the antitumor immune response.
By application, the cancer immunotherapy market is segmented as lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and other applications. The lung cancer market held the largest share in 2015 and is expected to lead the market during the alysis period owing to high incidence of lung cancer. Hospitals in end users held the largest market share of cancer immunotherapy market in 2015, and is projected to show the highest growth rate during the alysis period due to the extensive use of cancer immunotherapy in the hospitals.
Geographically, the global cancer immunotherapy market is alyzed by four regions, mely, North America, Europe, Asia-Pacific, and LAMEA. North America was the highest revenue contributor in 2015. This is attributed to the ample amount of expenditure in healthcare, well-established healthcare system, and high incidence of cancer. However, Asia-Pacific region is projected to be grow with the highest CAGR during the alysis period, owing to rise in healthcare expenditure, increase in per capita income, and improvement in healthcare infrastructure.
Key findings of the Cancer Immunotherapy Market:
The monoclol antibody accounted for the largest market share for technology segment in 2015 and is also estimated to grow at the highest CAGR of 15.0%.
By application, lung cancer held the highest market share and is anticipated to lead the market during the alysis period.
The U.S. was the major shareholder in the North American cancer immunotherapy market, accounting for six-seventh share in 2015.
Chi is expected to show the highest growth rate during the alysis period for the Asia-Pacific cancer immunotherapy market.
The major players profiled in the global cancer immunotherapy market are Amgen Inc., Advaxis Inc., Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, Immunomedics Inc., and Astrazeneca plc.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.